Nexstim Plc Updates its Future Outlook for the full year 2020

Company announcement, Insider information, Helsinki, 3 April 2020 at 09.00 am (EEST)Nexstim Plc Updates its Future Outlook for the full year 2020Nexstim Plc (NXTMH:HEX, NXTMS:STO) (“Nexstim” or “Company”) announces that due to the coronavirus COVID-19 pandemic having a negative impact on the Company’s business environment it’s no longer possible to give an accurate net sales estimate for the full year 2020 before the length of the health crisis is better known.The cost saving measures announced on 26 March 2020 are expected to decrease the full year 2020 operating loss in comparison to year 2019. The Company estimates that with these cost saving measures in place and loan repayments made according to earlier agreed schedules, the current working capital suffices then until end of Q3 2020.Updated Future Outlook: Full year 2020 operating loss is expected to decrease in comparison to year 2019.This updated future outlook replaces the previous financial guidance given on 28 February 2020, in which the Company estimated that based on its business forecast, the Company expected NBT business revenue to grow during year 2020 and a loss for the period was expected for the financial year 2020.NEXSTIM PLCMikko Karvinen, CEOFurther information is available on the website, or by contacting:Mikko Karvinen, CEO
+358 50 326 4101
Sisu Partners Oy (Certified Adviser)
Jussi Majamaa
+ 358 40 842 4479
About Nexstim PlcNexstim is a Finnish, globally operating medical technology company. Our mission is to enable personalized and effective therapies and diagnostics for challenging brain diseases and disorders.Nexstim has developed a world-leading non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.SmartFocus® technology is used in Nexstim’s proprietary Navigated Brain Therapy (NBT®) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT® system is CE marked for the treatment of major depression and chronic neuropathic pain.In addition, Nexstim is commercializing its SmartFocus® based Navigated Brain Stimulation (NBS) system for diagnostic applications. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain. Nexstim shares are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.For more information please visit www.nexstim.comAttachmentNexstim Plc COMPANY ANNOUNCEMENT_Updated Future Outlook for 2020_ENGLISH

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.